The agency said the pathway aims to improve access to breakthrough medical devices. The MDMA said it is disappointed by the ruling.
“We appreciate CMS’ efforts to improve the Coverage with Evidence Development pathway, but limiting eligibility to only five technologies a year means it is unlikely to meaningfully improve access or address disincentives to medical innovation caused by the current Medicare coverage process,” the organization said in a statement.
